Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart
failure cases and has a prevalence that is expected to rise with the growing ageing …

Background Obesity increases the risk of heart failure with preserved ejection fraction.
Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and …

Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous
clinical syndrome affected in its development and progression by many comorbidities. The …

Background Medical treatment for heart failure with preserved ejection (HFpEF) and heart
failure with mildly reduced ejection fraction (HFmrEF) has weaker evidence compared with …

Background Although beta-blockers are not recommended for the treatment of heart failure
with preserved ejection fraction (HFpEF) according to the latest European Society of …

Abstract Background and Aims Accelerated atrial pacing offers potential benefits for patients
with heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) …

Heart failure with preserved ejection fraction (HFpEF) constitutes approximately half of the
heart failure population, with its prevalence markedly increasing with older age and the …

Importance Increasing the patient's heart rate (HR) has emerged as a therapeutic option in
patients with heart failure with preserved ejection fraction (HFpEF). However, the evidence is …

Permanent pacing from the right ventricular apex can reduce quality of life and increase the
risk of heart failure and death. This review summarizes the milestones in the evolution of …

Abstract Purpose of Review To review the most recent clinical trials and data regarding
epidemiology, pathophysiology, diagnosis, and treatment of heart failure with preserved …